FDA — authorised 21 January 2025
- Application: NDA214759
- Marketing authorisation holder: MEDEXUS
- Local brand name: GRAFAPEX
- Indication: POWDER — INTRAVENOUS
- Status: approved
🇺🇸 Trecondi in United States
FDA authorised Trecondi on 21 January 2025
Marketing authorisations
FDA
- Status: approved
Trecondi in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Trecondi approved in United States?
Yes. FDA authorised it on 21 January 2025; FDA has authorised it.
Who is the marketing authorisation holder for Trecondi in United States?
MEDEXUS holds the US marketing authorisation.